ArticlePeerJ2026
Magnetic immunofluorescent microfluidic chips for rapid multi-parameter detection of serum antibodies to brucellosis and echinococcosis.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Brucellosis and echinococcosis are highly prevalent in pastoral areas, and traditional detection methods are limited because they are labor intensive, time consuming, and can only detect single-pathogens. This study aims to develop a magneto-immunofluorescent microfluidic chip for the rapid and simultaneous detection of serum antibodies against both brucellosis and echinococcosis and verify the detection performance and clinical application potential of the chip. Methods: In this study, a magneto-immunofluorescent microfluidic chip was designed, fabricated and optimized, with a focus on the conjugation ratios of Results: The chip stably and reliably detected eight target antibodies (AgB IgG, Ag5 IgG, Em2 IgG, Em18 IgG, LPS IgM, LPS IgG, OMP25 IgM, OPM25 IgG), with all key performance indicators meeting clinical requirements. It showed high consistency with ELISA: the positive and negative coincidence rates of all target antibodies exceeded 90%, Em18 IgG and LPS IgG achieved 100% positive coincidence rate, and Em18 IgG also had 100% negative coincidence rate; Kappa values ranged from 0.88 to 0.98 (far higher than the 0.75 threshold for good consistency), and more than 90% of samples fell within the 95% confidence interval in Bland-Altman analysis. Compared with ELISA, the chip had advantages of being a "one-chip multi-test", with low sample consumption, rapid detection, and simple operation, suitable for on-site screening in pastoral areas. Conclusions: The magneto-immunofluorescent microfluidic chip developed in this study enables the rapid and simultaneous detection of antibodies against brucellosis and echinococcosis, featuring excellent detection performance and high consistency with the gold standard method. This chip is expected to provide critical technical support for the early diagnosis, epidemiological surveillance, and precise prevention and control of both brucellosis and echinococcosis, thereby improving public health and preventing economic losses in the animal husbandry industry in high-prevalence regions of these two diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.